Moderna Cancer Vaccine Cuts Melanoma Risk in Trial

A personalized mRNA cancer vaccine developed by Moderna and Merck has shown remarkable success in preventing melanoma from returning.

The breakthrough sent Moderna's stock soaring 90% and offers new hope for treating cancer beyond COVID vaccines.